GlassScriptPhysician profile
Erik Brian Hurst
NPI 1801910880
$4,841.86
in general payments reported to CMS, 2019-2025
31 companies · $1,189 in 2025
The $1,189 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $122 · 2021: $592 · 2022: $535 · 2023: $845 · 2024: $1,101 · 2025: $1,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,928 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,927.57 |
| Education | $207.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $856.23 | 2019-2025 | |
| Organogenesis INC. | $623.79 | 2021-2025 | Cygnus Dual, Nushield, Simplimax |
| Novartis Pharmaceuticals Corporation | $548.38 | 2019-2025 | |
| Janssen Biotech, INC. | $413.57 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $340.13 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $250.67 | 2021-2025 | Ilumya, Winlevi |
| Amgen INC. | $181.02 | 2021-2024 | Otezla |
| Ucb, INC. | $179.35 | 2019-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.88 | 2022-2025 | Spevigo, Cyltezo |
| Regeneron Healthcare Solutions, INC. | $114.22 | 2022-2025 | Libtayo, Dupixent |
| Arcutis Biotherapeutics, INC. | $109.82 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $105.19 | 2022-2024 | Adbry |
| Galderma Laboratories, L.P. | $100.33 | 2024-2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Kerecis Limited | $90.56 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $85.82 | 2021-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $73.99 | 2022-2025 | Sotyktu |
| Convatec INC. | $73.49 | 2023-2024 | |
| Biofrontera INC. | $69.80 | 2021-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $62.38 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Strata Skin Sciences, INC. | $47.22 | 2023 | Xtrac |
| Genentech USA, INC. | $45.61 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $34.88 | 2024 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $34.50 | 2024 | Idacio |
| Pfizer INC. | $32.85 | 2022-2023 | |
| Celgene Corporation | $22.49 | 2019 | |
| Aclaris Therapeutics, INC. | $21.33 | 2019 | |
| Genzyme Corporation | $17.52 | 2021 | |
| Dusa Pharmaceuticals, INC. | $17.03 | 2019 | |
| Merck Sharp & Dohme LLC | $14.97 | 2019 | |
| Dermavant Sciences, INC. | $14.85 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Hurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.